Rosiptor clinical trials
Also written AQX-1125.
How each study uses rosiptor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Aquinox Pharmaceuticals (Canada) Inc. (7)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses rosiptor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain SyndromeTerminatedPhase 2Aquinox Pharmaceuticals (Canada) Inc.NCT03500159Written as AQX-1125 200 mg
- Pilot Efficacy and Safety Study of AQX-1125 in Atopic DermatitisCompletedPhase 2Aquinox Pharmaceuticals (Canada) Inc.NCT02324972Written as AQX-1125
- Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction StudyCompletedPhase 1Aquinox Pharmaceuticals (Canada) Inc.NCT03478020Written as AQX-1125
- Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain SyndromeStatus unknownPhase 3Aquinox Pharmaceuticals (Canada) Inc.NCT02858453Written as AQX-1125 100 mg
- Efficacy and Safety of AQX-1125 in IC/BPSCompletedPhase 2Aquinox Pharmaceuticals (Canada) Inc.NCT01882543Written as AQX-1125
- Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125CompletedPhase 1Aquinox Pharmaceuticals (Canada) Inc.NCT03185195Written as AQX-1125 Oral Tablet
- Efficacy and Safety of AQX-1125 in Unstable COPDCompletedPhase 2Aquinox Pharmaceuticals (Canada) Inc.NCT01954628Written as AQX-1125
Codes
What other systems call rosiptor · ClinicalTrials.gg INT006332
- UNII (FDA) 6R5034F862ROSIPTORConfirmed FDA, Wikidata
- Wikidata Q27074488rosiptorConfirmed FDA, Wikidata
- NCI Thesaurus C152258RosiptorOne source FDA
- DrugBank DB13012One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6R5034F862 | ROSIPTOR | Confirmed FDA, Wikidata |
| Wikidata | Q27074488 | rosiptor | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152258 | Rosiptor | One source FDA |
| DrugBank | DB13012 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.